Premium
Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters
Author(s) -
Dias J.P.,
Shardell M. D.,
Carlson O. D.,
Melvin D.,
Caturegli G.,
Ferrucci L.,
Chia C. W.,
Egan J. M.,
Basaria S.
Publication year - 2017
Publication title -
andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 43
eISSN - 2047-2927
pISSN - 2047-2919
DOI - 10.1111/andr.12284
Subject(s) - medicine , endocrinology , testosterone (patch) , insulin resistance , aromatase inhibitor , adiponectin , glucose homeostasis , placebo , homeostatic model assessment , leptin , insulin , aromatase , obesity , alternative medicine , pathology , cancer , breast cancer
Summary Testosterone (T) replacement is being increasingly offered to older men with age‐related decline in testosterone levels. The effects of long‐term testosterone replacement and aromatase inhibition ( AI ) on glucose homeostasis and cardiometabolic markers were determine in older non‐diabetic men with low testosterone levels. Men ≥65 years, mean age 71 ± 3 years with serum total T < 350 ng/dL were randomized in a double‐blind, placebo‐controlled, parallel‐group, proof‐of‐concept trial evaluating the effects of 5 g transdermal testosterone gel ( TT ) ( n = 10), 1 mg anastrozole ( n = 10) or placebo ( n = 9) daily for 12 months. Homeostatic Model Assessment of insulin resistance ( HOMA IR ) was the primary outcome. Secondary outcomes included OGIS in response to OGTT , fasting lipids, C‐reactive protein ( CRP ), adipokines, and abdominal and mid‐thigh fat by computed tomography. All outcomes were assessed at baseline and 12 months. After 12 months, absolute changes in HOMA IR in both treatment arms ( TT group: −0.05 ± 0.21); ( AI group: 0.15 ± 0.10) were similar to placebo (−0.11 ± 0.26), as were CRP and fasting lipid levels. Adiponectin levels significantly decreased in the TT group (−1.8 ± 0.9 mg/L, p = 0.02) and abdominal subcutaneous fat (−60.34 ± 3.19 cm 2 , p = 0.003) and leptin levels (−1.5 ± 1.2 ng/mL, p = 0.04) were significantly lower with AI . Mid‐thigh subcutaneous fat was reduced in both treatment arms ( TT group: −4.88 ± 1.24 cm 2 , p = 0.008); ( AI group: −6.05 ± 0.87 cm 2 , p = 0.0002). In summary, in this proof‐of‐concept trial, changes in HOMA IR AI were similar in all three groups while the effects of intervention on subcutaneous fat distribution and adipokines were variable. Larger efficacy and safety trials are needed before AI pharmacotherapy can be considered as a treatment option for low T levels in older men.